4.7 Meeting Abstract

Activity of systemic therapies after cabozantinib (CABO) in patients (pts) with metastatic renal cell carcinoma (mRCC)

Journal

ANNALS OF ONCOLOGY
Volume 31, Issue -, Pages S577-S577

Publisher

ELSEVIER
DOI: 10.1016/j.annonc.2020.08.815

Keywords

-

Categories

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available